OMCL vs. ANIP, KNSA, BKD, GMTX, AKRO, VIR, AGTI, MORF, GYRE, and PCRX
Should you be buying Omnicell stock or one of its competitors? The main competitors of Omnicell include ANI Pharmaceuticals (ANIP), Kiniksa Pharmaceuticals (KNSA), Brookdale Senior Living (BKD), Gemini Therapeutics (GMTX), Akero Therapeutics (AKRO), Vir Biotechnology (VIR), Agiliti (AGTI), Morphic (MORF), Gyre Therapeutics (GYRE), and Pacira BioSciences (PCRX). These companies are all part of the "medical" sector.
ANI Pharmaceuticals (NASDAQ:ANIP) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations.
ANI Pharmaceuticals presently has a consensus target price of $81.00, indicating a potential upside of 31.86%. Omnicell has a consensus target price of $42.20, indicating a potential upside of 38.63%. Given ANI Pharmaceuticals' higher possible upside, analysts plainly believe Omnicell is more favorable than ANI Pharmaceuticals.
ANI Pharmaceuticals has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.
ANI Pharmaceuticals has higher earnings, but lower revenue than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ANI Pharmaceuticals has a net margin of 6.87% compared to ANI Pharmaceuticals' net margin of -1.91%. Omnicell's return on equity of 17.15% beat ANI Pharmaceuticals' return on equity.
Omnicell received 65 more outperform votes than ANI Pharmaceuticals when rated by MarketBeat users. Likewise, 67.82% of users gave Omnicell an outperform vote while only 64.64% of users gave ANI Pharmaceuticals an outperform vote.
In the previous week, ANI Pharmaceuticals had 17 more articles in the media than Omnicell. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 6 mentions for Omnicell. ANI Pharmaceuticals' average media sentiment score of 1.12 beat Omnicell's score of 0.53 indicating that Omnicell is being referred to more favorably in the news media.
76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
ANI Pharmaceuticals beats Omnicell on 12 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Omnicell Competitors List
Related Companies and Tools
